Innovative Drug Discovery Platform Kangyuan BioCreation Secures Nearly RMB 100 Million Series A+ Financing Led by Matrix Partners China

VCBeat has learned that, recently,KYinno Biotechnology Co., Ltd. has completed an A+ round of financing amounting to nearly RMB 100 million. The round was led by Matrix Partners China, with participation from Yishang Huicheng, Shanlan Capital, and Yuanhui Ventures. This marks another significant milestone for KYinno following its A-round financing of over RMB 50 million earlier this year. Previously, the company had received investments from renowned institutions such as Pangu Ventures, Hanyi Capital, Yuansheng Venture Capital, and Queshan Capital.

KYinno is an innovative technology platform company specializing in new drug R&D services. It was co-founded by a team of scientists with many years of experience at internationally renowned CROs and biotechnology companies. Headquartered in the Beijing Economic-Technological Development Area, KYinno also maintains a business office in the United States. Since its establishment, KYinno has been dedicated to building innovative drug R&D technology platforms. The company has constructed the industry’s largest genetically engineered cell library, established mature GPCR antibody discovery technologies, and developed platforms including nanobodies, bispecific antibodies, gene-edited mice, and deficient CHO cell expression systems. Leveraging these capabilities, KYinno provides comprehensive technical services such as new drug target discovery and validation, antibody and small-molecule drug screening and discovery, and pharmacological and efficacy studies, thereby supporting clients’ innovative R&D efforts for antibody-based biologics and small-molecule chemical drugs. With a global orientation, KYinno has established strong collaborative relationships with more than 200 domestic and international clients since its inception, including several top-ten multinational pharmaceutical companies.

Dr. Ning Jinying, Chairman and CEO of the CompanyStatement: We express our gratitude to Matrix Partners China and all co-investors for their recognition of the KYinno team, and thank both new and existing shareholders for their steadfast support. Recently, the Center for Drug Evaluation (CDE) released the “Guiding Principles for Clinical Development of Antineoplastic Drugs with a Focus on Clinical Value (Draft for Comment),” setting higher standards for innovative drug development in China. Meanwhile, China’s new drug R&D capabilities are increasingly gaining recognition from developed countries in Europe and the United States; over the past year or more, the total value of licensing deals for Chinese innovative drugs has reached USD 15.9 billion. With broad prospects for innovation in China and a promising future for new drug development, KYinno will continue to uphold its philosophy of “Service and Innovation,” deepen its technological expertise, expand its product portfolio, enhance service quality, and move forward hand in hand with our valued customers.

Dr. Zhiyun Yu, Partner at Matrix Partners ChinaComment: KYinno’s founding team has extensive expertise in the antibody field, having developed a range of high-quality platforms spanning from cell-based to animal models, which have earned recognition from numerous partners in China. The company’s target discovery speed is also impressive. We hope KYinno will continue its efforts and bring original innovative drugs to market soon, benefiting patients across China.

Matrix Partners China, founded in 2008, is a leading venture capital firm in the industry with a long-term focus on early-stage and early-growth investments. It specializes in investing in intelligent manufacturing, hard technology, aerospace, consumer sectors, enterprise services & B2B & transaction platforms, healthcare, and other fields. To date, it has invested in more than 700 companies, including XPeng Motors, Li Auto, Guazi Used Cars, Ele.me, Youzan, Ronbay Technology, XGIMI Technology, Momo, Didi Chuxing, Zihai Guo, Genor Biopharma, Jian Ai, SiEngine Technology, and iSpace.

Yishang Huicheng Venture Capital Fund is a venture capital fund that makes equity investments in technologically innovative companies within China’s biomedical sector, with a focus on new drug development, novel biotechnological therapies, and new drug R&D service providers. The fund was jointly established by well-known publicly listed pharmaceutical companies, government industrial guidance funds, and other partners. All core members of the management team have more than ten years of experience in venture capital and scientific research management within the pharmaceutical and healthcare sectors, possessing deep industry backgrounds, extensive industry resources, and professional investment expertise. Yishang Venture Capital is committed to seizing industry opportunities, pooling professional expertise, facilitating corporate collaboration through resource integration, and empowering companies through investment to achieve mutual growth.

Shanlan Capital is a professional fund specializing in early- and growth-stage investments in the healthcare industry, with a focus on high-growth segments such as innovative medical devices, in vitro diagnostics (IVD), biotechnology, and medical artificial intelligence. The firm has invested in nearly 40 leading healthcare companies, including Guoke Hengtai, Deepwise Medical, Shengshi Taike, Baichen Medical, Zhishan Medical, Qianglian Zhichuang, and Weike Medical. Shanlan Capital’s core team comprises founders of publicly listed healthcare companies, as well as seasoned financial and strategic investment professionals. The firm provides value-added services to its portfolio companies in strategic planning, talent acquisition, and technological R&D, while also assisting them in integrating advanced international technologies and adopting global operational practices, thereby driving continuous innovation and development.

Yuanhui Capital was established in 2010 and has long been committed to exploring innovative models that integrate “venture capital with philanthropy.” With a long-term perspective, it seeks out entrepreneurial founders driven by purpose and growth-stage enterprises possessing hard-core technologies, investing in and accompanying them throughout their development. Guided by the philosophy of “ESG investment,” Yuanhui Capital promotes corporate upgrading toward “business for good,” facilitating a transition from mere “law-abiding operations that do no harm” to “high-quality, sustainable development.” Through an innovative model combining “venture capital, grant-making foundations, and modern grassroots philanthropy,” it helps enterprises achieve greater social value.

Yuanhui Capital has focused its investments on three key sectors—healthcare and pharmaceuticals, the chip industry, and new energy—since its establishment over a decade ago. It has invested in more than 50 high-quality enterprises, including: Sinocare [300298], Ausnutria Dairy [01717.HK], COL Group [300364], Silk Road Visual [300556], Maxscend Microelectronics [300782], Montage Technology [688008], JenKem Technology [688356], Nanocrystal Technologies (830933), Metaphor Tech, Shichuang Energy, Quzhi Technology, Yihong Intelligence, Innobio, Xiantong Pharma, Saifu Gene, Haijieya, Gaotu Xunda, Shenli Technology, Bangbangxing, Eishu Information, and Mingtai Electronics.